Background. Iron-deficiency anemia in non-dialysis-dependent chronic kidney disease (NDD-CKD) frequently requires parenteral iron replacement, but existing therapies often require multiple administrations. We evaluated the efficacy and cardiovascular safety of ferric carboxymaltose (FCM), a non-dextran parenteral iron permitting large single-dose infusions, versus iron sucrose in patients with iron-deficiency anemia and NDD-CKD. Methods. A total of 2584 participants were randomized to two doses of FCM 750 mg in one week, or iron sucrose 200 mg administered in up to five infusions in 14 days. The primary efficacy endpoint was the mean change to highest hemoglobin from baseline to Day 56. The primary composite safety endpoint included all-cause mortality, nonfatal myocardial infarction, nonfatal stroke, unstable angina, congestive heart failure, arrhythmias and hyper-and hypotensive events. Results. The mean hemoglobin increase was 1.13 g/dL in the FCM group and 0.92 g/dL in the iron sucrose group (95% CI, 0.13-0.28). Similar results were observed across all subgroups,
of life [1] . Among patients with CKD, the prevalence and severity of anemia are directly related to the degree of renal failure [2] . Although decreased erythropoietin production contributes to anemia in patients with CKD, iron deficiency due to dietary restriction, occult blood loss from the gastrointestinal tract, frequent laboratory testing and accelerated hemolysis also play significant roles [3, 4] .
Intravenous (IV) iron therapy is an accepted treatment regimen for the management of iron-deficiency anemia in patients with CKD [5] . Parenteral iron therapies available in the USA include iron dextran, sodium ferric gluconate (SFG), iron sucrose and ferumoxytol. Typical therapeutic courses of iron dextran, SFG or iron sucrose require 5-10 injections of 100-200 mg doses of each. Ferumoxytol (Feraheme; AMAG Pharmaceuticals, Inc., Cambridge, MA), is an iron oxide with a carbohydrate coating that was approved by the Food and Drug Administration (FDA) for the treatment of anemia in CKD in 2009 [6] . It is given as two 510-mg injections 3-8 days apart [6] for a maximum treatment dose of 1020 mg. Thus, with the exception of ferumoxytol, most available IV iron preparations require frequent administrations that increase costs and are more inconvenient to patients and healthcare providers [7] , and may thus reduce compliance.
Ferric carboxymaltose (FCM) (Injectafer; Luitpold Pharmaceuticals, Shirley, NY) is an IV iron preparation whose properties permit administration of even larger single doses (750 mg) over short periods of time [8] for a maximum treatment dose of 1500 mg. Previous studies have shown that FCM is efficacious and well tolerated in a variety of settings, including CKD [9, 10] , congestive heart failure [11] , inflammatory bowel disease [12] , anemia related to the postpartum period [13] , heavy menstrual bleeding [14] and anemia associated with cancer and chemotherapy [15] .
In our study, the Randomized Evaluation of Efficacy and Safety of FCM in Patients with Iron-Deficiency Anemia and Impaired Renal Function (REPAIR-IDA), we sought to evaluate the cardiovascular safety and efficacy of IV FCM compared with IV iron sucrose in patients with irondeficiency anemia and non-dialysis-dependent CKD (NDD-CKD).
M AT E R I A L S A N D M E T H O D S

Study design
The design of the REPAIR-IDA trial has been described [16] . Briefly, REPAIR-IDA (NCT00981045) was a randomized, active-controlled, multicenter, noninferiority, open-label trial comparing the safety and efficacy of IV FCM with IV iron sucrose (Venofer; Luitpold Pharmaceuticals, Shirley, NY) in subjects with iron-deficiency anemia and NDD-CKD. REPAIR-IDA was conducted from September 2009 to June 2011 at 187 US centers in accordance with US federal regulations, institutional review board requirements and the Declaration of Helsinki. All participants provided written informed consent.
Patient population
Consenting patients ≥18 years of age were eligible. Participants were required to have a hemoglobin value of ≤11.5 g/dL and chronically impaired renal function as defined by (1) glomerular filtration rate (GFR) <60 mL/min/1.73 m 2 [measured using the modification of diet in renal disease (MDRD) method] on two consecutive measurements during screening, or (2) GFR <90 mL/min/1.73 m 2 on two measurements during screening and at least one of the following: kidney damage as indicated by a documented history of urine composition abnormalities and/or elevated risk of cardiovascular disease (Category 2 or 3) based on the Framingham Model [17] .
The diagnosis of iron-deficiency anemia for inclusion in this trial was based on two screening hemoglobin concentrations measured in a central laboratory within 7 days that were required to be within 0.7 mg/dL of each other and with an average hemoglobin measurement of ≤11.5 g/dL. Eligibility criteria also included a screening visit ferritin ≤100 ng/mL, or ferritin ≤300 ng/mL when transferrin saturation (TSAT) was ≤30%, and a stable erythropoiesis-stimulating agent (ESA) dose (±20%) for 4 weeks prior to randomization in participants taking an ESA. A complete list of study eligibility criteria is available in Supplementary Appendix Table S1 .
Treatment
Eligible participants were randomly allocated in a 1:1 ratio to receive open-label FCM or iron sucrose and stratified according to the baseline hemoglobin measurement (≤9, 9.1-10.0 and ≥10.1 g/dL), baseline cardiovascular risk (history of myocardial infarction, stroke or congestive heart failure), region, ESA use and CKD stage. The randomization schedule was generated prior to study start and the treatment group was assigned using an interactive voice-response system.
For subjects assigned to receive FCM, the study drug was administered at a dose of 15 mg iron/kg as an undiluted IV push at a rate of 100 mg/min (maximum cumulative dose 750 mg) on Days 0 and 7, for a maximum total dose of 1500 mg. Subjects assigned to IV iron sucrose received the study drug at a dose of 200 mg of iron administered as an undiluted IV push over 2-5 min on Days 0, 7 and 14, with two additional doses given between Days 0 and 7 and between Days 7 and 14, for a total of five doses (1000 mg). All subjects were monitored for serious acute reactions, including hypotension, loss of consciousness, bronchospasm, shortness of breath and seizures during and after infusions. In addition, based on the previous observations of clinically insignificant and transient, self-limited hypophosphatemia associated with FCM, serum phosphate levels were checked at multiple study visits and subjects were monitored closely for the development of potentially clinically significant changes in serum phosphate levels.
All open-label study drug (FCM and iron sucrose) was provided by the study sponsor (Luitpold). Inventories were controlled by investigators and verified by study monitors according to the protocol.
Study endpoints
The primary efficacy outcome was mean change from baseline hemoglobin to highest observed hemoglobin at any time between the baseline and the end of treatment period (Day 56) or the time of intervention. Secondary efficacy measures included the proportion of subjects achieving an increase in hemoglobin of ≥1 g/dL any time between baseline and Day 56 and the mean changes from baseline to highest observed ferritin and TSAT between baseline and Day 56. The primary safety endpoint was the proportion of study participants experiencing at least one treatment-emergent adverse event included in a primary composite safety endpoint, beginning on or after the first dose of randomized treatment. The primary composite safety endpoint included all-cause death, nonfatal myocardial infarction, nonfatal stroke, unstable angina requiring hospitalization, congestive heart failure requiring hospitalization or medical intervention, cardiac arrhythmia and hypertensive or hypotensive events as defined by protocol (Supplementary Appendix).
Events were adjudicated in a blinded fashion by an independent clinical events classification committee at the Duke Clinical Research Institute, Durham, NC. Secondary safety endpoints included the proportion of study participants who died, time to first event included in the composite safety endpoint, proportion of participants reporting treatment-emergent adverse events, proportion of participants reporting treatment-emergent serious adverse events and incidence of treatment-emergent, potentially clinically significant laboratory and vital sign values.
Statistical analysis
The safety analysis population comprised all participants who received a randomly assigned treatment dose. The primary population for evaluating all efficacy endpoints was the modified intent-to-treat population, defined as subjects from the safety population who received at least one dose of randomly assigned study medication, had at least one postbaseline hemoglobin assessment and had a stable (±20%) dose of ESA (including no ESA) for 4 weeks prior to randomization. Summaries of efficacy and clinical laboratory results include data from the treatment phase (through Day 56) only. Summaries of the primary composite safety endpoint and adverse events include all data through the treatment and follow-up phases (to Day 120).
Noninferiority of FCM to iron sucrose for change from baseline to highest hemoglobin between baseline and Day 56 was assessed with a two-sided 95% confidence interval (CI) and a noninferiority margin of −0.2 g/dL. Noninferiority of FCM to iron sucrose for the proportion of participants achieving an increase in hemoglobin of ≥1 g/dL any time between baseline and Day 56 was assessed with a two-sided 95% CI and a noninferiority margin of −7.5%. For safety analysis, comparisons between FCM and IV iron sucrose in the proportion of participants experiencing the primary composite endpoint were assessed with a two-sided 95% CI constructed with the normal approximation to the binomial with continuity correction. Hazard ratios were assessed using a Cox proportional model. All statistical tests were at the 0.05 alpha level, two-tailed unless stated otherwise. No adjustments were made for exploratory subgroup analyses. All analyses were performed using SAS version 9 (SAS Institute, Cary, NC).
A sample size of 1250 patients per study arm was deemed to be sufficient to provide evidence of equivalent cardiovascular risk between the two groups if the 95% CI included zero. A sample size of 2500 provided >95% power to demonstrate noninferiority with a 95% CI and a noninferiority margin of a −0.2 g/dL difference in mean increase in hemoglobin levels between baseline and Day 56 for FCM versus iron sucrose [16] .
R E S U LT S
A total of 2584 study participants were randomly allocated to receive FCM (n = 1290) or iron sucrose (n = 1294). Of these, 14 participants allocated to FCM and 9 allocated to iron sucrose were discontinued from the study prior to dosing. Ultimately, 1276 participants were treated with FCM and 1285 were treated with iron sucrose (Figure 1 ). Baseline demographic and clinical characteristics of participants are provided in Table 1 . No clinically significant differences were observed in patient demographics, iron indices, CKD status or baseline laboratory values.
During the treatment phase, the mean [standard deviation (SD)] total dose of iron received was 1464 (158) mg in the FCM group and 963 (138) mg in the iron sucrose group. The majority of participants in the FCM group (96.8%) received two infusions, and the majority in the iron sucrose group (91.6%) received five infusions. Adherence to treatment phase as scheduled was similar between groups (82.1 versus 81.1%, respectively).
Changes in mean (SD) hemoglobin from the baseline to the highest value between baseline and Day 56 by treatment arm stratified by baseline hemoglobin, ESA use and CKD stage are shown in Table 2 . Overall, the mean increase in hemoglobin was 1.13 (1.04) in the FCM group and 0.92 (0.92) in the iron sucrose group (95% CI, 0.13-0.28), thus demonstrating the noninferiority (i.e. the lower limit of two-sided 95% CI of treatment comparison was ≥−0.2) of FCM to iron sucrose. Although this study was designed and powered for noninferiority, the CI for the primary treatment comparison was entirely above zero for the primary treatment comparison for efficacy, thus achieving the pre-specified criterion for noninferiority as well as the unplanned criterion for statistical superiority for the 1500-mg FCM regimen at the 5% confidence level. When analyzed by baseline hemoglobin, ESA use, and CKD stage, mean increases in hemoglobin were numerically greater for FCM across all subgroups and demonstrated noninferiority to iron sucrose for all comparisons, except Stage 2 CKD. Using the lower limit of two-sided 95% CI >0 threshold, FCM also demonstrated statistical superiority over iron sucrose with respect to mean hemoglobin increases for participants with baseline hemoglobin ≥10.1 g/dL, CKD Stage 3-4, and any or no ESA use.
The mean hemoglobin values at each scheduled visit are shown in Figure 2A . Overall, the proportion of participants achieving an increase in hemoglobin of ≥1.0 g/dL at any time between baseline and Day 56 demonstrated noninferiority of FCM to iron sucrose ( Table 3 ). The proportion was significantly greater in the FCM group [48.6% (607/1249) versus 41.0% (510/1244); 95% CI, 3.6 to 11.6%]. When analyzed by baseline hemoglobin, ESA use and CKD stage, noninferiority of FCM was again demonstrated for all comparisons except baseline hemoglobin levels of ≤9 g/dL and Stage 5 CKD. The mean increases in ferritin, TSAT and serum iron from the baseline to the highest value by Day 56 were also significantly greater in the FCM group when compared with iron sucrose. The mean ferritin and TSAT values at each scheduled visit are shown in Figure 2B and C.
A total of 175/1276 participants (13.7%) in the FCM group and 156/1285 subjects (12.1%) in the iron sucrose group met the primary composite safety endpoint (95% CI, −1.10-4.25%). Protocol-defined hypertensive events were significantly more common in the FCM group compared with the iron sucrose group (7.5 versus 4.4%; 95% CI, 1.19-4.99%). In contrast, more subjects in the iron sucrose group experienced protocol-defined hypotensive events than did subjects in the FCM group (3.2 versus 1.8%; 95% CI, −2.67 to −0.10%). When protocol-defined hyper-and hypotensive events were excluded, 70 of 1276 participants (5.5%) in the FCM group and 69 of 1285 (5.4%) in the iron sucrose group met the primary composite safety endpoint (95% CI, −1.72-1.95%). A total of 24 of 1276 (1.9%) participants in the FCM group and 35 of 1285 (2.7%) in the iron sucrose group had adjudicated events of death due to any cause, nonfatal myocardial infarction or nonfatal stroke. A summary of the components of the primary composite safety endpoint by treatment is presented in Table 4 . A time-to-first-event analysis for events comprising the composite safety endpoint excluding protocol-defined hypertensive and hypotensive events is shown in Figure 3 . † Denotes modified intent-to-treat population (includes all subjects in the safety population who had at least 1 post-baseline hemoglobin assessment and had stable (within 20%) dosing with erythropoiesis-stimulating agent for 4 weeks (including a dose of 0) prior to randomization.
During the study period, 33 participants died: 15 of 1276 (1.2%) in the FCM group and 18 of 1285 (1.4%) in the iron sucrose group (95% CI, −1.18-0.73%). No death was considered by the investigator to be related to the study drug, except for one death from cardiac arrhythmia in an 86-yearold study participant with iron-deficiency anemia, CKD, diastolic dysfunction, supraventricular/ventricular tachycardia, bradycardia and type 2 diabetes who was found unresponsive at home 1 day after receiving a dose of FCM. The event was considered by the site investigator to be possibly related to the study drug.
During the study, at least one drug-related treatment-emergent adverse event occurred in 298 of 1276 (23.4%) subjects in the FCM group and 202 of 1285 (15.7%) subjects in the iron sucrose group. The most common events were nausea (8.6% in the FCM group versus 1.6% for iron sucrose), hypertension (4.6 versus 2.0%), flushing (3.0 versus 0.1%), dizziness (2.4 versus 1.2%) and dysgeusia (2.4 versus 1.2%). Most of the drug-related treatment-emergent adverse events were severity Grade 1 or 2.
The majority of drug-related treatment-emergent adverse events were mild or moderate in severity. At least one serious adverse event was experienced by 202 of 1276 (15.8%) participants receiving FCM and 197 of 1285 (15.3%) participants receiving iron sucrose (P = 0.74), with congestive heart failure being the most common event reported (2.4 versus 2.3%; P = 
O R I G I N A L A R T I C L E
F e r r i c c a r b o x y m a l t o s e f o r i r o n -d e fi c i e n c y a n e m i a 0.90). With the exception of anemia requiring intervention [14/1276 (1.1%) for FCM versus 4/1285 (0.3%) for iron sucrose; P = 0.02], there were no significant differences between groups in the occurrence of any serious adverse events. Moreover, all cases of anemia in the FCM group were considered unrelated to the study agent by the investigator. A total of 11 participants (9 FCM, 2 iron sucrose) experienced hypersensitivity events during the study. All of these were Grade 1 or 2 in severity, with the exception of one Grade 3 reaction in the FCM group that occurred 33 days after the first infusion and was considered unrelated to the study agent by the investigator. The reactions prompted interruption or discontinuation of therapy in two of the nine FCM subjects and in one of the two iron sucrose subjects.
Although the mean phosphorus levels at baseline were the same (4.11 mg/dL) for both the treatment groups, the proportion of subjects with potentially clinically significant decreases in phosphorus was higher in the FCM group compared with the iron sucrose group [213/1154 (18.5%) versus 9/1131 (0.8%)]. In addition, greater mean decreases in phosphorus from baseline to nadir (−1.28 versus −0.66 mg/ dL) and from baseline to Day 56 (−0.39 versus −0.09 mg/dL) were observed in the FCM group versus the iron sucrose group. Importantly, no hypophosphatemia was associated with a serious adverse event.
Greater mean increases in alkaline phosphatase and gamma-glutamyl transpeptidase from baseline to Day 56 were observed in the FCM group compared with the iron sucrose group. These changes were not associated with significant changes in bilirubin in either group. One participant assigned to iron sucrose had elevations of aspartate transaminase, alanine transaminase and alkaline phosphatase ≥3 × upper limit of normal (ULN) and a total bilirubin of >2 × ULN on Day 56 (earlier liver panel results had been normal). A serious event of cholestatic jaundice and a non-serious event of "gallbladder disorder" were also reported for this participant and were considered by the investigator to be unrelated to the study drug. Transaminases returned to normal levels on Day 59.
D I S C U S S I O N
The REPAIR-IDA trial is the first and largest head-to-head comparison of two IV iron therapies for treatment of irondeficiency anemia in patients with NDD-CKD. FCM delivered as two 750-mg doses given 1 week apart was demonstrated to be noninferior to a typical dosing strategy of iron sucrose with regard to the primary efficacy endpoint of mean change from baseline hemoglobin to highest observed hemoglobin at any time between the baseline and the end of treatment period (Day 56) or the time of intervention. Although this study was designed and powered for noninferiority, the CI for the primary treatment comparison was entirely above zero for the primary treatment comparison for efficacy, thus achieving the pre-specified criterion for noninferiority as well as the unplanned criterion for statistical superiority of the FCM regimen at the 5% confidence level. In addition, the proportion of subjects with an increase in hemoglobin of ≥1.0 g/dL over the baseline value was significantly greater in the FCM group compared with the iron sucrose group. The significant mean increases in ferritin, TSAT, and serum iron were also observed in the FCM group, and analysis by the baseline hemoglobin value, use of ESA and CKD stage demonstrated noninferiority of FCM versus iron sucrose for nearly all prespecified subgroup comparisons.
Both FCM and iron sucrose treatments were well tolerated, and no significant differences in the number of adjudicated events meeting the primary composite safety endpoint were observed between treatment groups. Protocol-specified hypertensive and hypotensive events were the most commonly occurring components of the composite safety endpoint in either group. Although hypertensive events were more common in the FCM group than in the iron sucrose group, the vast majority of these events in the FCM group occurred on the day of an iron infusion and were transient, resolving within 30 min of infusion. In contrast, nearly twice as many hypertensive events in the iron sucrose group occurred on non-dosing days, necessitating unscheduled visits, hospital admission or a change in medical treatment. Hypotensive events were also more common in the iron sucrose group than in the FCM group. When the hyper-and hypotensive events were excluded from analysis, the two groups were virtually identical with respect to the number of subjects with one or more composite safety endpoint events.
There were numerically more (difference not statistically significant) patients with unstable angina and arrhythmias in the FCM group. Despite the higher number of potentially clinically unstable patients in the FCM group, there was no difference in the primary composite safety endpoint between these two groups. Furthermore, no event of unstable angina, heart failure, stroke or myocardial infarction occurred within 14 days of the iron infusion (and hypertensive event). More specifically, the onset dates for the composite safety endpoint event in patients who also experienced a protocol-defined hypertensive event were heart failure (FCM: 17 and 106 days; iron sucrose: 31 and 62 days); unstable angina (FCM: 25, 64 and 85 days); stroke (FCM: 22 days); myocardial infarction and hypertensive crisis (iron sucrose: 15 days). Thus, the hypertensive events related to the respective iron infusions did not appear to be associated with the development of another (delayed) safety event, further underscoring the safety of FCM.
The only laboratory finding of note was the higher proportion of potentially clinically significant low phosphorus in the FCM group compared with the iron sucrose group. The hypophosphatemia observed in the FCM group was transient and not associated with the development of a serious adverse event. Similar non-clinically significant decreases in phosphate levels have been observed in trials of FCM under other longterm conditions such as inflammatory bowel disease [12] and heavy uterine bleeding [14] . One proposed explanation is that FCM transiently increases the levels of the full-length (intact) form of fibroblast growth factor 23, a hormone that reduces renal tubular reabsorption of phosphate, leading to temporary reductions in plasma phosphate levels [18] .
We note that participants assigned to FCM received a higher cumulative dose of iron than did participants assigned to iron sucrose (1500 mg versus 1000 mg). The iron sucrose regimen of 200 mg × 5 infusions was chosen for this study because it is the current FDA-approved dose for this comparator. While we cannot, therefore, conclude with certainty that the observed benefits of FCM over iron sucrose are solely the result of improved efficacy of FCM, this study has demonstrated that FCM allows more iron to be administered safely in fewer infusions and over a shorter period of time than iron sucrose. Additionally, early and sustained increases in hemoglobin, ferritin and TSAT in the FCM group compared with Table 3 . Proportion of subjects with an increase in hemoglobin ≥1.0 g/dL between baseline and Day 56 or time of intervention (modified intent-to-treat population)
Study group FCM (n = 1249)n/N (%)
Iron sucrose (n = 1244)n/N (%) During the observation period immediately following study drug administration, hypertension was defined as an increase in systolic blood pressure >20 mm Hg that resulted in a value of >180 mm Hg or an increase in diastolic blood pressure >15 mm Hg that resulted in a value of >105 mm Hg. c During the observation period immediately following study drug administration, hypotension was defined as a decrease in systolic blood pressure >20 mm Hg that resulted in a value of <90 mm Hg or a decrease in diastolic blood pressure >15 mm Hg that resulted in a value of <50 mmHg.
the iron sucrose group at each study point suggest enhanced bioavailability of FCM relative to iron sucrose as was proposed in a previous trial comparing FCM with iron sucrose in irondeficiency anemia patients undergoing hemodialysis [19] . As mentioned previously, these findings lead to the conclusion that FCM may have the potential to provide a cost savings relative to iron sucrose, a current standard parenteral iron formulation, as a result of fewer required office visits or hospital admissions. Perhaps even more clinically relevant, however, is the observation that up to 50% more iron in the form of FCM can be administered rapidly to patients with CKD while maintaining a safety profile comparable with that of iron sucrose. A formal cost analysis was not performed as part of this trial, but two non-US cost analyses comparing FCM and iron sucrose in patients with anemia due to inflammatory bowel disease have both demonstrated FCM to be more cost-effective than iron sucrose [12, 20] , and a recent Spanish analysis comparing FCM with iron sucrose for the outpatient treatment of iron-deficiency anemia in patients with gastrointestinal diseases [21] also suggests a favorable cost-effectiveness profile for FCM. However, these studies were small, single-center evaluations, and their findings may not be generalizable to other healthcare settings and payment systems.
An important limitation of this trial is its relatively short follow-up period (120 days), which does not allow us to characterize the long-term safety of FCM therapy in this population with regard to the primary safety endpoint components of death, nonfatal myocardial infarction, nonfatal stroke and unstable angina. However, at the time the trial was designed, all deaths subsequent to FCM use in the FCM clinical trial database (none of which was considered related to the study drug by the investigator) had occurred within 120 days of study drug use [22] . We also note that patients receiving FCM demonstrated a numerically higher incidence of treatmentrelated adverse events other than those comprising the primary safety endpoint, including nausea, flushing, dizziness and hypersensitivity events. These differences were not statistically significant, although it is conceivable that some of the events resulted from the higher dose of iron received in the FCM arm. More importantly, however, the vast majority of adverse events were mild or moderate in severity, and there were no differences in serious adverse events between the two treatment groups that were considered related to treatment.
In conclusion, our results indicate that when compared with iron sucrose administered as five infusions of 200 mg each, FCM administered as two infusions of 750 mg given 1 week apart is a safe and efficacious alternative for the treatment of iron-deficiency anemia in the setting of CKD. FCM has the advantage of allowing more iron to be administered in fewer infusions in patients with CKD.
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